Immunization of preterm infants with 10-valent pneumococcal conjugate vaccine

Pediatrics

Volumn 128, Issue 2, 2011, Pages

  Omeñaca, Félix ^a   Merino, Jose Manuel ^b   Tejedor, Juan Carlos ^c   Constantopoulos, Andreas ^d   Papaevangelou, Vassiliki ^e   Kafetzis, Dimitrios ^e   Tsirka, Antigoni ^f   Athanassiadou, Fani ^g   Anagnostakou, Marina ^h   François, Nancy ⁱ   Borys, Dorota ⁱ   Schuerman, Lode ⁱ  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^c HOSPITAL DE MÓSTOLES   (Spain)

^d IASO   (Greece)

^e UNIVERSITY OF ATHENS   (Greece)

^f G HATZIKOSTA GENERAL HOSPITAL   (Greece)

^g AHEPA UNIVERSITY HOSPITAL   (Greece)

^h AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

ⁱ GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Immune response; Pneumococcal conjugate vaccine; Premature infants; Safety; Streptococcus pneumoniae

Indexed keywords

BACTERIUM ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; PNEUMOCOCCUS VACCINE;

ANOREXIA; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAIN; APPLICATION SITE SWELLING; ARTICLE; CHILD; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DROWSINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GESTATION PERIOD; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; PREMATURITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SEROTYPE; SIDE EFFECT;

FEMALE; HUMANS; IMMUNIZATION, SECONDARY; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VACCINATION; VACCINES, CONJUGATE;

EID: 80051489278     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-1184     Document Type: Article

References (22)

1. Mahon BE, Ehrenstein V, Norgaard M, Pedersen L, Rothman KJ, Sorensen HT. Perinatal risk factors for hospitalization for pneumococcal disease in childhood: a population-based cohort study. Pediatrics. 2007;119(4). Available at:www.pediatrics.org/cgi/content/full/119/4/e804
2. Shinefield H, Black S, Ray P, Fireman B, Schwalbe J, Lewis E. Efficacy, immunogenicityandsafety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J. 2002;21(3):182-186 (Pubitemid 34214132)
3. Esposito S, Pugni L, Bosis S, et al. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months postnatally to pre- and full-term infants. Vaccine. 2005;23(14):1703-1708 (Pubitemid 40215704)
4. Ruggeberg JU, Collins C, Clarke P, et al. Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants. Vaccine. 2007;25(2):264-271 (Pubitemid 44856082)
5. Adam D, Fehnle K. Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine coadministered with routine vaccine combinations. Vaccine. 2008;26(47):5944-5951
6. Bermal N, Szenborn L, Chrobot A, et al. The 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr Infect Dis J. 2009;28(suppl 4):S89-S96
7. Chevallier B, Vesikari T, Brzostek J, et al. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr Infect Dis J. 2009;28(suppl 4):S109-S118
8. Knuf M, Szenborn L, Moro M, et al. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J. 2009;28(suppl 4):S97-S108
9. Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet. 2009;374(9698):1339-1350
10. Silfverdal SA, Hogh B, Bergsaker MR, et al. Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine. Pediatr Infect Dis J. 2009;28(10):e276-e282
11. Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J. 2009;28(suppl 4):S66-S76
12. Wysocki J, Tejedor JC, Grunert D, et al. Immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different Neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J. 2009;28(suppl 4):S77-S88
13. Saari TN. Immunization of preterm and low birth weight infants. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics. 2003;112(1 pt 1):193-198
14. Concepcion NF, Frasch CE. Pneumococcal type polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme- linkedimmunosorbentassay.ClinDiagn Lab Immunol. 2001;8(2):266-272
15. Henckaerts I, Goldblatt D, Ashton L, Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol. 2006;13(3):356-360
16. Poolman JT, Frasch CE, Kayhty H, Lestrate P, Madhi SA, Henckaerts I. Evaluation of pneumococcal polysaccharide immunoassays using a adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol. 2010;17(1):134-142
17. Romero-Steiner S, Libutti D, Pais LB, et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol. 1997;4(4):415-422 (Pubitemid 27321773)
18. Henckaerts I, Durant N, De Grave D, Schuerman L, Poolman J. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine. 2007;25(13):2518-2527 (Pubitemid 46366133)
19. Zepp F, Schmitt HJ, Cleerbout J, Verstraeten T, Schuerman L, Jacquet JM. Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines. 2009;8(6):663-678
20. Omeñaca F, Garcia-Sicilia J, Garcia-Corbeira P, et al. Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue. Pediatrics. 2005;116(6):1292-1298 (Pubitemid 46056474)
21. Omeñaca F, Garcia-Sicilia J, Boceta R, Sistiaga-Hernando A, Garcia-Corbeira P. Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children whowereborn prematurely. Pediatr Infect Dis J. 2007;26(9):824-829 (Pubitemid 47329855)
22. Atkinson WL, Kroger AL, Pickering LK. General immunization practices. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 5th ed. New York, NY: Elsevier; 2008:83-109